Literature DB >> 18270458

Insulin response to oral glucose load is associated with coronary artery disease in subjects with normal glucose tolerance.

Tetsuro Miyazaki1, Kazunori Shimada, Yoshitaka Iwama, Atsumi Kume, Katsuhiko Sumiyoshi, Yayoi Sato, Hirotoshi Ohmura, Yoshiro Watanabe, Hiroshi Mokuno, Hiroyuki Daida.   

Abstract

AIM: The critical role of hyperinsulinemia, independent of hyperglycemia, in the pathogenesis of atherosclerosis has not been fully determined. We investigated the association between secretion patterns of insulin after oral glucose load and the severity of coronary artery disease (CAD) in patients with normal glucose tolerance (NGT).
METHODS: We enrolled 116 subjects with NGT from 243 patients who had undergone coronary angiography and a standard 75-g oral glucose tolerance test. The patients were divided into 0-vessel, single-vessel and multi-vessel disease groups on the basis of the severity of CAD.
RESULTS: The 2-h insulin levels in the multi-vessel disease group (p=0.005) and the single-vessel disease group (p<0.05) were significantly higher than those in the 0-vessel disease group. Multivariate analysis revealed that the levels of 2-h insulin were an independent variable for the presence of CAD (p=0.02) after adjustment for gender and the presence of each criterion of metabolic syndrome using the definition of the International Diabetes Federation.
CONCLUSION: A slight but significant increase in prolonged insulin secretion, which is associated with the early stage of insulin resistance, in subjects with NGT, may play an important role in the pathogenesis of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270458     DOI: 10.5551/jat.e515

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN: 1340-3478            Impact factor:   4.928


  5 in total

1.  Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT).

Authors:  Kosuke Fukao; Kazunori Shimada; Makoto Hiki; Takashi Kiyanagi; Kuniaki Hirose; Atsumi Kume; Hiromichi Ohsaka; Rie Matsumori; Takeshi Kurata; Tetsuro Miyazaki; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2011-09-10       Impact factor: 9.951

2.  Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention.

Authors:  Shuhei Takahashi; Kazunori Shimada; Katsumi Miyauchi; Tetsuro Miyazaki; Eiryu Sai; Manabu Ogita; Shuta Tsuboi; Hiroshi Tamura; Shinya Okazaki; Tomoyuki Shiozawa; Shohei Ouchi; Tatsuro Aikawa; Tomoyasu Kadoguchi; Hamad Al Shahi; Takuma Yoshihara; Makoto Hiki; Kikuo Isoda; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2016-10-11       Impact factor: 9.951

3.  Effects of Glycemic Index and Cereal Fiber on Postprandial Endothelial Function, Glycemia, and Insulinemia in Healthy Adults.

Authors:  Glenn A Gaesser; Jessica Rodriguez; James T Patrie; Corrie M Whisner; Siddhartha S Angadi
Journal:  Nutrients       Date:  2019-10-06       Impact factor: 5.717

4.  Postloading insulinemia is independently associated with arterial stiffness in young Japanese persons.

Authors:  Norimitsu Murai; Naoko Saito; Sayuri Nii; Yuto Nishikawa; Asami Suzuki; Eriko Kodama; Tatsuya Iida; Kentaro Mikura; Hideyuki Imai; Mai Hashizume; Yasuyoshi Kigawa; Rie Tadokoro; Chiho Sugisawa; Kei Endo; Toru Iizaka; Fumiko Otsuka; Shun Ishibashi; Shoichiro Nagasaka
Journal:  Hypertens Res       Date:  2021-09-13       Impact factor: 3.872

5.  Low 1,5-anhydroglucitol levels are associated with long-term cardiac mortality in acute coronary syndrome patients with hemoglobin A1c levels less than 7.0.

Authors:  Shohei Ouchi; Kazunori Shimada; Tetsuro Miyazaki; Shuhei Takahashi; Yurina Sugita; Megumi Shimizu; Azusa Murata; Tomoyasu Kadoguchi; Takao Kato; Tatsuro Aikawa; Shoko Suda; Eiryu Sai; Masaru Hiki; Hiroshi Iwata; Takatoshi Kasai; Katsumi Miyauchi; Hiroyuki Daida
Journal:  Cardiovasc Diabetol       Date:  2017-11-21       Impact factor: 9.951

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.